In a previous study we found that a TaySachs disease (TSD) causing mutation in the intron 9 donor splice site of the HEXA gene occurs at high frequency in nonJewish patients and carriers from the British Isles. It was found more frequently in subjects of Irish, Scottish, and Welsh origin compared with English origin (63% and 31% respectively). We have now tested, in a blind study, 26 American TSD carriers and 28 non-carriers who have British ancestry for the intron 9 splice site mutation. Six of the carriers and none of the controls were positive for the mutation. All six had Irish ancestry, compared with nine of the 20 other (intron 9 mutation negative) TSD carriers (p < 0 05). These results confirm the previously found high frequency of the intron 9 mutation in non-Jewish TSD families of British Isles, particularly Irish, origin, and reinforce the need to screen such families for this mutation.
Tay-Sachs disease (TSD)
mutation by PCR amplification and direct sequencing, as previously described.9 Samples were scored for the presence or absence of the mutation without previous knowledge of carrier status as determined by enzyme assay. Six were positive, all of whom were from the 'carrier' group. Some of the samples had been tested previously for other TSD causing mutations, namely the exon 1 1 insert, the intron 12 splice site mutation, a glycine269 to serine substitution which causes adult onset TSD, and also a benign mutation in exon 7.1O All had been negative for all mutations tested. None of the 28 subjects designated non-carriers by enzyme analysis was tested for other mutations.
Results and discussion At the time of sampling, each of the 54 subjects listed up to four countries of origin of their grandparents. Table 1 shows the number of intron 9 positive TSD carriers, intron 9 negative TSD carriers, and non-carriers who gave each country as one of those from which their grandparents originated.
As shown in table 2, all six of the intron 9 positive TSD carriers had at least one Irish Landels, Green, Ellis, Fensom, Kaback, Lim-Steele, Zeiger, Levy, Bobrow French origin. Thus of the subjects carrying the intron 9 mutation, all but two could trace their ancestry to central or western Europe (of those where ancestral information was known). The G to A transition has occurred at a CpG mutation 'hot spot' and therefore has an increased chance of recurrence. However, this mutation has now been reported in so many non-Jewish TSD patients that an independent mutational event in each case seems unlikely. Perhaps a more reasonable explanation is that some of these apparently unrelated patients do have common origins; haplotype analysis will be needed to determine whether they share a common genetic background. Recurrence might explain the presence of this mutation in subjects of completely different ethnic origin, such as the Mexican patient reported by Akerman et al. '2 Clearly the intron 9 mutation is a frequent cause of TSD in non-Jewish patients of European origin, and is especially frequent in patients from (or with ancestors from) the British Isles. While studies of European origin TSD patients show a frequency of this mutation of 11% or 16%, this study of TSD carriers with British Isles ancestry showed the intron 9 mutation to be present in 23%. Our previous study of TSD patients and carriers living in the British Isles showed that the intron 9 mutation accounted for 42% of disease alleles, and 63% in patients from Ireland, Scotland, or Wales.
The results of this study confirm the high frequency of the intron 9 mutation in nonJewish TSD carriers with British Isles ancestry, and emphasise the need to screen nonJewish TSD families of European, particularly UK and Irish origin, for this mutation. 
